Zobrazeno 1 - 10
of 147
pro vyhledávání: '"James R. Porter"'
Autor:
Gopal Sharma, Milap Shah, Puneet Ahluwalia, Prokar Dasgupta, Benjamin J Challacombe, Mahendra Bhandari, Rajesh Ahlawat, Sudhir Rawal, Nicolo M Buffi, Ananthakrishnan Sivaraman, James R Porter, Craig Rogers, Alexandre Mottrie, Ronney Abaza, Khoon Ho Rha, Daniel Moon, Yuvaraja B Thyavihally, Dipen J Parekh, Umberto Capitanio, Kris K Maes, Francesco Porpiglia, Levent Turkeri, Gagan Gautam
Publikováno v:
Indian Journal of Urology, Vol 38, Iss 4, Pp 288-295 (2022)
Introduction: Outcomes of robot-assisted partial nephrectomy (RAPN) depend on tumor complexity, surgeon experience and patient profile among other variables. We aimed to study the perioperative outcomes of RAPN for patients with complex renal masses
Externí odkaz:
https://doaj.org/article/5452c3d230084d01aca47fde4c6279f7
Autor:
James R Porter, Samarpit Rai
Publikováno v:
Urology Video Journal, Vol 14, Iss , Pp 100157- (2022)
Objectives: The early adoption of robotic partial nephrectomy was mainly via the transperitoneal approach [1] due to increased working space, familiar landmarks and ease of access. However, the retroperitoneal approach for robotic partial nephrectomy
Externí odkaz:
https://doaj.org/article/8cecc5933f764b32af6baa44c4d95c5f
Autor:
Gopal, Sharma, Milap, Shah, Puneet, Ahluwalia, Prokar, Dasgupta, Benjamin J, Challacombe, Mahendra, Bhandari, Rajesh, Ahlawat, Sudhir, Rawal, Nicolo M, Buffi, Ananthakrishnan, Sivaraman, James R, Porter, Craig, Rogers, Alexandre, Mottrie, Ronney, Abaza, Khoon Ho, Rha, Daniel, Moon, Thyavihally B, Yuvaraja, Dipen J, Parekh, Umberto, Capitanio, Kris K, Maes, Francesco, Porpiglia, Levent, Turkeri, Gagan, Gautam
Publikováno v:
European Urology Focus. 9:345-351
Ability to predict the risk of intraoperative adverse events (IOAEs) for patients undergoing partial nephrectomy (PN) can be of great clinical significance.To develop and internally validate a preoperative nomogram predicting IOAEs for robot-assisted
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3e323ed8debfba137c984066019ab320
https://doi.org/10.1016/j.euf.2022.09.004
https://doi.org/10.1016/j.euf.2022.09.004
Autor:
Antoin Douglawi, Alireza Ghoreifi, Umberto Carbonara, Wesley Yip, Robert G. Uzzo, Vitaly Margulis, Matteo Ferro, Ottavio De Cobelli, Zhenjie Wu, Giuseppe Simone, Riccardo Mastroianni, Koon H. Rha, Daniel D. Eun, Adam C. Reese, James R. Porter, Ithaar Derweesh, Reza Mehrazin, Giuseppe Rosiello, Riccardo Tellini, Marcus Jamil, Alexander Kenigsberg, Jason M. Farrow, William P. Schrock, Giovanni Cacciamani, Abhishek Srivastava, Amit S. Bhattu, Alexandre Mottrie, Mark L. Gonzalgo, Chandru P. Sundaram, Firas Abdollah, Andrea Minervini, Riccardo Autorino, Hooman Djaladat
Publikováno v:
Clinical Genitourinary Cancer.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::48048c8ec40378652f08e7f544ca2151
https://doi.org/10.1016/j.clgc.2023.05.011
https://doi.org/10.1016/j.clgc.2023.05.011
Autor:
Gopal Sharma, Milap Shah, Puneet Ahluwalia, Prokar Dasgupta, Benjamin J. Challacombe, Mahendra Bhandari, Rajesh Ahlawat, Sudhir Rawal, Nicolo M. Buffi, Ananthakrishanan Sivaraman, James R. Porter, Craig Rogers, Alexandre Mottrie, Ronney Abaza, Khoon Ho Rha, Daniel Moon, Thyavihally B. Yuvaraja, Dipen J. Parekh, Umberto Capitanio, Kris K. Maes, Francesco Porpiglia, Levent Turkeri, Gagan Gautam
Publikováno v:
European Urology Oncology.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e9b8c55f06e757becbfdbaa15183d35
https://doi.org/10.1016/j.euo.2023.04.005
https://doi.org/10.1016/j.euo.2023.04.005
Autor:
Jessica J. Lin, Henry E. Pelish, Aaron N. Hata, Monika A. Davare, Viola Zhu, Matthew D. Shair, James R. Porter, Nancy E. Kohl, John R. Soglia, Yuting Sun, Scot Mente, Satoshi Yoda, Katelyn S. Nicholson, Clare Keddy, Adam Acker, Linh Nguyen-Phuong, Anthonie J. van der Wekken, D. Ross Camidge, Shirish M. Gadgeel, Sai-Hong Ignatius Ou, Benjamin Besse, Anupong Tangpeerachaikul, Joshua C. Horan, Alexander Drilon
NVL-520 Modeling, Properties, Biochemical Activity, Cellular Activity, and In Vivo Activity
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::179b478fa795d20f06c52f43443d2a80
https://doi.org/10.1158/2159-8290.22542255
https://doi.org/10.1158/2159-8290.22542255
Autor:
Jessica J. Lin, Henry E. Pelish, Aaron N. Hata, Monika A. Davare, Viola Zhu, Matthew D. Shair, James R. Porter, Nancy E. Kohl, John R. Soglia, Yuting Sun, Scot Mente, Satoshi Yoda, Katelyn S. Nicholson, Clare Keddy, Adam Acker, Linh Nguyen-Phuong, Anthonie J. van der Wekken, D. Ross Camidge, Shirish M. Gadgeel, Sai-Hong Ignatius Ou, Benjamin Besse, Anupong Tangpeerachaikul, Joshua C. Horan, Alexander Drilon
ROS1 tyrosine kinase inhibitors (TKI) have been approved (crizotinib and entrectinib) or explored (lorlatinib, taletrectinib, and repotrectinib) for the treatment of ROS1 fusion–positive cancers, although none of them simultaneously address the nee
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04fc95b4f0ef39c29165338ddd307aa5
https://doi.org/10.1158/2159-8290.c.6549846
https://doi.org/10.1158/2159-8290.c.6549846
Autor:
James E Steward, Linhui Wang, Georgi Guruli, Daniel Eun, Mark L. Gonzalgo, Riccardo Tellini, Alessandro Veccia, Robert G. Uzzo, Amit S Bhattu, Ahmad Almujalhem, Alexander Mottrie, Qi Chen, Hooman Djaladat, Riccardo Autorino, Andrea Minervini, Alireza Ghoreifi, Ithaar Derweesh, Alyssa Danno, Giuseppe Simone, Antoin Douglawi, James R. Porter, Vitaly Margulis, Elio Mazzone, Zhenjie Wu, Ali Al-Qathani, Fady Ghali, Giovanni Cacciamani, Koon Ho Rha, Matteo Ferro, Reza Mehrazin, Aeen Asghar, Andrea Mari, Chandru P. Sundaram, Firas Abdollah, Jamil Marcus, Abhishek Srivastava
Publikováno v:
European Urology Focus. 8:173-181
Background Postoperative renal function impairment represents a main limitation for delivering adjuvant chemotherapy after radical nephroureterectomy (RNU). Objective To create a model predicting renal function decline after minimally invasive RNU. D
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c8231d1c4b02990472d7341a9dd1a6b3
https://doi.org/10.1016/j.euf.2021.01.014
https://doi.org/10.1016/j.euf.2021.01.014
Autor:
Alexander Drilon, Joshua C. Horan, Anupong Tangpeerachaikul, Benjamin Besse, Sai-Hong Ignatius Ou, Shirish M. Gadgeel, D. Ross Camidge, Anthonie J. van der Wekken, Linh Nguyen-Phuong, Adam Acker, Clare Keddy, Katelyn S. Nicholson, Satoshi Yoda, Scot Mente, Yuting Sun, John R. Soglia, Nancy E. Kohl, James R. Porter, Matthew D. Shair, Viola Zhu, Monika A. Davare, Aaron N. Hata, Henry E. Pelish, Jessica J. Lin
Publikováno v:
Cancer discovery.
ROS1 tyrosine kinase inhibitors (TKI) have been approved (crizotinib and entrectinib) or explored (lorlatinib, taletrectinib, and repotrectinib) for the treatment of ROS1 fusion–positive cancers, although none of them simultaneously address the nee
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7334032e18993114652aa175371035e9
https://pubmed.ncbi.nlm.nih.gov/36511802
https://pubmed.ncbi.nlm.nih.gov/36511802
Autor:
Geert De Naeyer, James R. Porter, Alex Mottrie, Giovanni Lughezzani, Ruben De Groote, Massimo Lazzeri, Alessandro Uleri, Paolo Casale, Pietro Diana, Nicolò Maria Buffi, Rodolfo Hurle, Alberto Saita
Publikováno v:
European Urology Focus. 7:1100-1106
Background The use of a nephron-sparing surgery for the treatment of localized renal masses is being pushed to more challenging cases. However, this procedure is not devoid of risks, and the Radius, Exophytic/Endophytic, Nearness, Anterior/Posterior,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e21bfba336529eaf0f48d3a24eeca3dc
https://doi.org/10.1016/j.euf.2020.11.003
https://doi.org/10.1016/j.euf.2020.11.003